Shots:

• The P-III (Ri-CoDIFy) study contains (Ri-CoDIFy 1 & 2) that evaluates ridinilazole (BID for 10 days) vs vancomycin (4 times daily for 10 days) in a ratio (1:1) in 759 patients with C. diff. inf. & sustained clinical response. Patients who received ridinilazole were provided with 2 PBO pills/day to maintain consistency of administration b/w 2 arms
• The study showed that ridinilazole resulted in a higher observed SCR rate than vancomycin but failed to meet the 1EPs for superiority & no recurrence of the infection @30 days
• The results were published in a peer-reviewed medical journal. The company continues to evaluate the data along with an additional analysis including analyses specific to the microbiome

Ref: Globe NewsWire | Image: Summit